234 related articles for article (PubMed ID: 34571876)
21. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
Bai J; Liang P; Li Q; Feng R; Liu J
Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
[TBL] [Abstract][Full Text] [Related]
22. Determinants of Resistance to Checkpoint Inhibitors.
Tran L; Theodorescu D
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111080
[TBL] [Abstract][Full Text] [Related]
23. Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis.
Boutros A; Bruzzone M; Tanda ET; Croce E; Arecco L; Cecchi F; Pronzato P; Ceppi M; Lambertini M; Spagnolo F
Eur J Cancer; 2021 Dec; 159():154-166. PubMed ID: 34753012
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.
Owoyemi I; Vaughan LE; Costello CM; Thongprayoon C; Markovic SN; Herrmann J; Otley CC; Taner T; Mangold AR; Leung N; Herrmann SM; Kukla A
Cancer; 2020 Nov; 126(21):4780-4787. PubMed ID: 32786022
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint inhibitors in people living with HIV: what about anti-HIV effects?
Abbar B; Baron M; Katlama C; Marcelin AG; Veyri M; Autran B; Guihot A; Spano JP
AIDS; 2020 Feb; 34(2):167-175. PubMed ID: 31634190
[TBL] [Abstract][Full Text] [Related]
26. Resistance to immune checkpoint inhibitors and the tumor microenvironment.
Kawashima S; Togashi Y
Exp Dermatol; 2023 Mar; 32(3):240-249. PubMed ID: 36437644
[TBL] [Abstract][Full Text] [Related]
27. Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates.
Rust BJ; Kean LS; Colonna L; Brandenstein KE; Poole NH; Obenza W; Enstrom MR; Maldini CR; Ellis GI; Fennessey CM; Huang ML; Keele BF; Jerome KR; Riley JL; Kiem HP; Peterson CW
Blood; 2020 Oct; 136(15):1722-1734. PubMed ID: 32614969
[TBL] [Abstract][Full Text] [Related]
28. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
[TBL] [Abstract][Full Text] [Related]
29. Preconditioning of the immune system modulates the response of papillary thyroid cancer to immune checkpoint inhibitors.
Pani F; Yasuda Y; Rousseau ST; Bermea KC; Roshanmehr S; Wang R; Yegnasubramanian S; Caturegli P; Adamo L
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521928
[TBL] [Abstract][Full Text] [Related]
30. Predictive Value of
Chen XJ; Ren AQ; Zheng L; Zheng ED
Front Immunol; 2021; 12():664847. PubMed ID: 33953726
[TBL] [Abstract][Full Text] [Related]
31. A Network Comparison on Safety Profiling of Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Yan YD; Cui JJ; Fu J; Su YJ; Chen XY; Gu ZC; Lin HW
Front Immunol; 2021; 12():760737. PubMed ID: 34925331
[TBL] [Abstract][Full Text] [Related]
32. Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care.
Singh S; Numan A; Agrawal N; Tambuwala MM; Singh V; Kesharwani P
Int Immunopharmacol; 2020 Jun; 83():106417. PubMed ID: 32200155
[TBL] [Abstract][Full Text] [Related]
33. New developments in the mechanism and application of immune checkpoint inhibitors in cancer therapy (Review).
Wang Y; Yang S; Wan L; Ling W; Chen H; Wang J
Int J Oncol; 2023 Jul; 63(1):. PubMed ID: 37326100
[TBL] [Abstract][Full Text] [Related]
34. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
Rallis KS; Hillyar CRT; Sideris M; Davies JK
Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
[TBL] [Abstract][Full Text] [Related]
35. Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy.
Chiu CY; Chang JJ; Dantanarayana AI; Solomon A; Evans VA; Pascoe R; Gubser C; Trautman L; Fromentin R; Chomont N; McMahon JH; Cameron PU; Rasmussen TA; Lewin SR
J Immunol; 2022 Jan; 208(1):54-62. PubMed ID: 34853078
[TBL] [Abstract][Full Text] [Related]
36. Immune Checkpoint Inhibitor Can Reduce HCV-RNA without Liver Damage.
Fukuda R; Sugawara S; Kondo Y
Intern Med; 2020 Sep; 59(18):2245-2248. PubMed ID: 32522918
[TBL] [Abstract][Full Text] [Related]
37. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
38. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.
Bagchi S; Yuan R; Engleman EG
Annu Rev Pathol; 2021 Jan; 16():223-249. PubMed ID: 33197221
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Pan J; Liu Y; Guo X; Bai Z; Levi Sandri GB; Méndez-Sánchez N; Qi X
Expert Opin Drug Saf; 2022 Oct; 21(10):1275-1287. PubMed ID: 36214583
[TBL] [Abstract][Full Text] [Related]
40. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
Front Immunol; 2021; 12():651086. PubMed ID: 34248939
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]